Navigation Links
Cutting caffeine may help control diabetes
Date:1/27/2008

se from the blood and into muscle and other cells in the body where it is used for fuel. It may also be that caffeine triggers the release of adrenaline the fight or flight hormone that we know can also boost sugar levels.

Either way, he says, the higher sugar levels that result from caffeine are bad news for diabetic patients.

There are no current guidelines suggesting diabetics shouldnt drink coffee, but Lane says that day may come, if further studies bear out their findings.

Coffee is such a common drink in our society that we forget that it contains a very powerful drug caffeine. Our study suggests that one way to lower blood sugar is to simply quit drinking coffee, or any other caffeinated beverages. It may not be easy, but it doesnt cost a dime, and there are no side effects, Lane says.


'/>"/>

Contact: Michelle Gailiun
michelle.gailiun@duke.edu
919-684-4148
Duke University Medical Center
Source:Eurekalert

4

GOOD

Page: 1 2

Related medicine news :

1. New Democracy Corps Battleground Poll of Swing Districts Finds Strong, Bi-Partisan Opposition to Cutting Medicare-Funded Nursing Home Care
2. FDA Mulls Cutting Salt in Processed Foods
3. Financial incentives may hold key to cutting child malaria deaths
4. Cutting Edge CyberKnife Cancer Treatment Center to Open in Tampa Bay Area
5. The era of global aging: GSA showcases cutting-edge San Francisco meeting topics
6. Fern Tree, The Spa at Half Moon, Jamaicas Premier Spa, Opens With Ceremonial Ribbon Cutting
7. Prize for Cutting-Edge Laser Innovations
8. Cutting Salt Wont Affect Foods Safety
9. Over 500,000 Health Care Providers Now Cutting Costs, Saving Time Through CAQH Administrative Simplification Initiative
10. Caffeine May Lower Ovarian Cancer Risk
11. Ovarian cancer risk not affected by alcohol and smoking, but reduced by caffeine
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 2Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 3Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 4Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 5ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 2ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 3ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 4The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 2The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 3The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 4The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 5Video 3A Plan for Long Term Care Before the Crisis Hits 47797 1Video 3A Plan for Long Term Care Before the Crisis Hits 47797 2Video 3A Plan for Long Term Care Before the Crisis Hits 47797 3Video 3A Plan for Long Term Care Before the Crisis Hits 47797 4Five Cord Blood Transplant Centers in Catalonia and Valencia Join a Study to Test a New Technique to Treat Leukemia and Lymphoma 12449 1Five Cord Blood Transplant Centers in Catalonia and Valencia Join a Study to Test a New Technique to Treat Leukemia and Lymphoma 12449 2Five Cord Blood Transplant Centers in Catalonia and Valencia Join a Study to Test a New Technique to Treat Leukemia and Lymphoma 12449 3Stepping up minority recruiting 47791 1Stepping up minority recruiting 47791 2Stepping up minority recruiting 47791 3